English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Ayahuasca in a Pill: What the Push to Standardize the Brew Really Means
A pill version of ayahuasca. Read that again. The brew that Amazonian peoples have prepared in clay pots for centuries — the one that takes hours to cook, smells like wet earth and burnt molasses, and tastes like something your worst enemy might serve you — is now being engineered into a standardized capsule by a Canadian biotech firm. If you've been following the psychedelics space, you saw this coming. The race to medicalize plant medicine has been gathering speed for a few years now, and ayahuasca was always going to land in someone's lab. The question isn't really whether it would happen. It's what happens next — to the science, to the ceremony, and to the Indigenous communities whose knowledge made the medicine possible in the first place. Filament Health, a Canadian company working in the natural-products end of the psychedelic industry, announced it's developing a standardized extract drawn from the two plants traditionally used to brew ayahuasca: the chacruna shrub (Psychotria viridis) and the vine known across the Amazon as cipó-mariri or yagé (Banisteriopsis caapi). The chacruna leaf provides DMT, the molecule largely responsible for ayahuasca's famous visions. The vine contains MAO inhibitors — the chemical key that allows DMT, normally broken down in the gut, to reach the brain when taken orally. Without one, the other doesn't work. That pharmacological partnership is part of why ayahuasca has fascinated researchers and Indigenous peoples alike: it's a piece of biochemical sophistication that was figured out in the rainforest long before anyone could spell tryptamine. Filament's pitch is that their extract preserves the full chemical fingerprint of both plants — the alkaloids, the beta-carbolines, the supporting compounds — rather than just synthesizing DMT and harmine separately. They're banking on something the cannabis world calls the entourage effect: the idea that the whole plant matrix does something more nuanced than its isolated parts. And unlike a traditional brew, where potency swings wildly from one batch and one curandero to the next, a pill can be dosed to the milligram. For clinical research, this is a real argument. A 2018 trial at Brazil's Federal University of Rio Grande do Norte showed ayahuasca producing rapid and lasting improvements in patients with treatment-resistant depression — the kind of result that turns heads at psychiatric conferences. But that study used brew sourced from a Barquinha church, and the next study elsewhere would use a different brew with a different chemical profile. Reproducing results across labs becomes a guessing game. A standardized capsule sidesteps that. Phase I and Phase II trials need known doses. The FDA needs known doses. Insurance companies, eventually, will need known doses. If ayahuasca is going to enter mainstream addiction recovery and mental-health care — and there are credible reasons to think it could help with depression, PTSD, and substance dependence — somebody, at some point, has to put it in a form regulators can stamp. Filament has partnered with the University of California San Francisco's translational psychedelic research group on this work. Their psilocybin extract program is further along (Phase II); the ayahuasca side is still early. Here's where it gets uncomfortable. Ayahuasca is not an invention. It is, by every honest account, a gift of Indigenous Amazonian knowledge — refined across hundreds of generations by Shipibo, Asháninka, Shuar, Cofán, and dozens of other peoples who don't get cited in patent filings. The Nagoya Protocol, an international biodiversity treaty most countries have signed, requires that any commercial use of traditional biological knowledge involve prior informed consent from the source communities and a real benefit-sharing arrangement. Not a press release. Not a vague promise. An actual agreement. When asked which Indigenous groups had consented to Filament's project, the company's CEO said they'd consulted with communities in Peru but declined to name them or share details, citing the early stage of research. That answer hasn't satisfied anyone who's been watching this space. The 4th Indigenous Ayahuasca Conference — which gathered representatives from 35 traditional groups — issued a clear public statement against the patenting and commercialization of ayahuasca. They didn't leave room for interpretation. Beatriz Labate, the anthropologist who runs the Chacruna Institute and has spent her career inside this conversation, asked the questions a lot of us are asking: These aren't rhetorical jabs. They're the actual ethical hinges this whole industry will swing on. Short answer: not really. Ayahuasca itself isn't patentable in any honest legal sense — there's no novel invention in something humans have been brewing since before writing existed. A U.S. patent issued in 1986 on a strain of Banisteriopsis caapi was eventually overturned after years of Indigenous-led legal pressure, and that case set an important precedent. What companies can patent are extraction methods, stabilization processes, specific formulations. Filament could plausibly hold IP on how it pulls the alkaloids out, how it preserves them, how it dose-standardizes the capsule. That's where the legal architecture sits — and where the ethical fight will keep happening. Some companies are trying to get ahead of this. Journey Colab, which is developing a synthetic mescaline therapy for alcohol use disorder, published what they call a patent pledge: a public commitment not to enforce their patents against traditional and ceremonial uses of peyote and San Pedro. They've also set aside 10% of founding equity in a Reciprocity Trust benefiting Indigenous communities and equitable-access programs. Filament has said it's looking at something similar, and notes that 10% of its own founding shares went to a separate Filament Foundation focused on the broader natural-psychedelic space. Whether these pledges become real, enforceable structures or marketing language is something we'll only know in five or ten years. The track record of pharma making good on benefit-sharing promises is, let's say, mixed. If you're reading this because you're weighing a ceremony, the pill conversation might feel abstract. It's not. Here's how it touches the decision you're actually making: Plant medicines are walking a path that cannabis, kratom, and dozens of other botanicals walked before them: from sacred or folk use, through research, into pharmaceuticals, and eventually onto a shelf. Each transition extracts something — usually the molecules — and leaves something behind. The leaving-behind is what Indigenous leaders keep trying to name. None of this means clinical ayahuasca research is wrong. Treatment-resistant depression is brutal, and so is the addiction epidemic that's killing people in numbers we've stopped being able to process. If a standardized extract can reach patients who'd never make it to Peru, that's not nothing. But the path matters. How it gets to those patients — whose knowledge it was built on, who shares in the benefit, whether the forest and the people who tend it are protected — those questions don't disappear because the science is promising. If you're curious about experiencing the traditional form before the conversation tips further toward pharmaceuticals, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, ask the hard questions — of the company selling the pill, of the retreat selling the ceremony, and honestly, of yourself about why you're drawn to either one.
Psychedelics as Medicine: Where Psilocybin, MDMA and Ayahuasca Stand Now
A few years ago, suggesting that magic mushrooms might be on a regulatory glide path toward becoming an approved medicine would have gotten you a polite eye-roll at most dinner parties. Today, that same conversation is happening at Davos, in peer-reviewed journals, and in the offices of biotech investors who quietly want a piece of the action. Psychedelics — once shorthand for sixties counterculture — have re-entered medicine through a side door, and they brought ayahuasca, psilocybin, MDMA and a few other plant-based and synthetic compounds with them. If you're somewhere on the spectrum between curious and quietly desperate — maybe weighing a retreat for depression, addiction, or trauma that hasn't budged with conventional care — it's worth understanding what's actually going on. Not the hype version. The real one. The shift didn't happen overnight. It started with small, almost stubborn pilot studies. Cancer patients facing terminal diagnoses were given a single supervised dose of psilocybin and many of them described, weeks later, that their fear of dying had loosened its grip. Combat veterans with treatment-resistant PTSD sat through MDMA-assisted therapy sessions and reported that the intrusive flashbacks finally let them sleep. And people with depression that hadn't responded to multiple antidepressants tried ayahuasca in clinical settings — the same brew Amazonian healers have used for generations — and some of them came out the other side genuinely different. That's the pattern researchers keep pointing at. These compounds appear to do something for the people who haven't been helped by anything else. And the dose required to see results is, in most cases, startlingly small. One or two supervised sessions. Not a daily pill for life. The phrase that keeps coming up among scientists in the field is cautious optimism. As one prominent neuroscientist at Imperial College London put it during a session on the new science of psychedelics: the climate's looking good. Which, coming from a researcher who has spent his career on this, is roughly the equivalent of a normal person yelling from a rooftop. Two compounds are leading the regulatory pack, and they treat very different things. Psilocybin — the active molecule in magic mushrooms — has shown its sharpest results in severe depression, particularly the treatment-resistant kind where someone has tried four, five, six different antidepressants without meaningful change. In supervised sessions, a single dose alongside therapy seems to crack something open. Not a cure, exactly. More like a window that lets the patient see their own situation from outside it, long enough to make the changes that the depression had been blocking. MDMA — yes, the same molecule that's been dancing through clubs for forty years — is being studied as an adjunct to talk therapy for post-traumatic stress disorder. The drug doesn't do the work alone. It quiets the fear response just enough that the patient can actually talk about what happened without dissociating or shutting down. The therapist does the rest. Other compounds are on the docket too. Ketamine, a partial psychedelic, is already being prescribed off-label for depression in many countries. Ibogaine — derived from an African shrub — is being explored for opioid addiction, often in retreat settings outside the US because of its legal status. And ayahuasca itself, the South American brew of Banisteriopsis caapi vine and DMT-containing leaves, has its own growing research footprint, especially around depression and addiction. This is the question I get asked most, usually in a quieter voice than the others. The honest answer: the evidence is genuinely promising, but it's also still early, and the gap between a clinical trial and a jungle retreat is wider than people want to admit. What we know: The mechanism, as best researchers can tell, isn't that the substance scrubs the addiction away. It's that a well-prepared psychedelic experience seems to give people a kind of bird's-eye view of their own life — their relationships, their pain, the patterns they've been re-enacting. From up there, the addiction often looks less like an identity and more like a strategy that stopped working. That insight is what people then carry into the difficult work of staying changed. None of this means a single ceremony will fix anything. People who do well with plant medicine for addiction almost always combine it with therapy, community, and a meaningful change in daily life. The retreat is a pivot point, not a finish line. I'd be doing you a disservice if I painted this as risk-free. It isn't, and reputable facilitators will say so before they say anything else. A few things worth knowing if you're considering a psychedelic retreat: Assume you've decided this is worth exploring. Here's the rough shape of due diligence I'd want you to do before handing over any money. Medical screening. A serious retreat will ask about your medications, mental-health history, cardiovascular health, and family psychiatric history before they'll take your deposit. If the intake process is just a credit card form, that's a red flag. Move on. Facilitator lineage and training. Whether the leaders trained in a traditional Amazonian context, a Western therapeutic model, or both, they should be able to explain it clearly. Vague answers — "I've been called to this work" without specifics — are worth pausing on. Group size and ratio. Twelve participants with two facilitators is reasonable. Thirty participants with two facilitators is a crowd, not a ceremony. Ask before you book. What happens after. Is there integration support included? A group call two weeks out? Recommended therapists in your home country? The aftermath is where many people quietly struggle, and the best retreats build for it. Honest pricing. A well-run plant-medicine retreat generally runs somewhere between $1,500 and $5,000 for a week, depending on country, accommodation, and reputation. Substantially cheaper often means corners cut. Substantially more expensive often means you're paying for thread count, not better outcomes. The current expectation among researchers is that the first formally approved psychedelic medicine — most likely psilocybin for severe depression, or MDMA for PTSD — will be available through regulated clinical channels within the next few years in several countries. The investment money has arrived. The clinical evidence keeps strengthening. The cultural conversation has shifted from are these drugs? to how do we deliver them responsibly? That doesn't mean retreats become obsolete. For many people — especially those drawn to traditional Amazonian ceremonies, or those whose conditions don't map neatly onto a clinical diagnosis — the retreat path will remain meaningful long after psilocybin shows up at the local clinic. The two worlds are different doors into related rooms. What's changed is that the conversation is finally serious. You're no longer choosing between fringe ceremony and skeptical doctor. You're choosing among several legitimate paths, each with its own trade-offs, and you get to pick the one that fits your situation. If something here speaks to you, the ayahuasca and psychedelic retreats discussed across the wider plant-medicine community can be browsed and booked on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the right retreat for you is the one you booked after asking every question, not the one you booked because the calendar pressured you into it.
How to Choose an Ayahuasca Retreat: A Practical Guide for First-Timers
So you've read the books. Watched the documentaries. Listened to enough podcast interviews to recognize the names of half a dozen shamans you've never met. And now you're staring at a browser tab full of ayahuasca retreats wondering which one won't end with you having a panic attack in a hammock surrounded by strangers — or worse. Good. That hesitation is healthy. Choosing where to drink ayahuasca is not the same as choosing a yoga retreat or a beach holiday. The stakes are higher, the variables are murkier, and the marketing photos all look suspiciously similar. After years of sitting in ceremony and talking with facilitators across Peru, Costa Rica, the Netherlands, and a handful of grey-zone spots in North America, I can tell you the difference between a solid center and a sketchy one is rarely obvious from a homepage. Here's what actually matters when you're picking a place to sit. Every center will tell you it's safe. That's the floor, not the ceiling. The real question is whether the operation is built around safety as a structural commitment — medical screening, trained staff, emergency protocols — or whether "safe" is just a word on the About page next to a stock photo of a hummingbird. Start with the intake process. A reputable retreat will ask you for a detailed medical history before they take your deposit. SSRIs, MAOI interactions, heart conditions, history of psychosis in the family — these are non-negotiable disqualifiers or at minimum require a careful taper protocol. If a center waves through your booking without a real screening conversation, that's a red flag the size of a billboard. Ayahuasca interacts dangerously with a long list of medications and conditions, and any operator who treats that casually is gambling with your nervous system. Ask about the brew itself. The traditional recipe is two plants: Banisteriopsis caapi (the vine) and chacruna or chaliponga (the DMT-containing leaf). Some centers add other admixtures — toé (Brimadenia grandiflora) being the most concerning. Toé is a powerful and unpredictable plant that can produce terrifying, dissociative experiences and has been linked to genuinely dangerous incidents. You have every right to ask exactly what's in the cup. If the answer is vague or defensive, keep looking. The person pouring the medicine matters more than the décor of the maloca. Traditional curanderos train for years — often decades — within specific lineages: Shipibo, Cofán, Quechua, Santo Daime, União do Vegetal, and others. Each lineage has its own songs (icaros), its own protocols, its own relationship with the plants. None is inherently better, but they are genuinely different, and a serious center will be transparent about who trained their healers and where. Look for centers that name their shamans and tell you something about their background. "Our shaman has 30 years of experience" is not enough. With whom? In what tradition? Is there a way to verify any of it? You'd be surprised how many "shamans" in the gringo retreat circuit have, on closer inspection, learned the basics over a weekend and bought a feathered headdress online. Pay attention to the support team too. A good ceremony usually involves: The ratio of staff to participants tells you a lot. If there are twenty drinkers and one facilitator, nobody's getting the attention they need when things get hard at 2 a.m. Legality is the first thing to sort out, because it shapes everything else. Ayahuasca is fully legal in Peru, Brazil, Ecuador, and Colombia, where it's recognized as cultural heritage or protected through religious-use frameworks. In the Netherlands, the situation is murkier than it used to be — Santo Daime churches have run there for years, but recent court decisions have complicated things. In the United States, ayahuasca remains federally illegal outside of two specific religious exemptions (UDV and Santo Daime), which means any commercial "ayahuasca retreat" operating in the U.S. is doing so without legal cover, no matter what their website implies. That doesn't automatically make domestic retreats unsafe, but it does mean fewer guardrails. If something goes wrong, the recourse is thinner. Most experienced practitioners I respect still recommend traveling to a country where the medicine is legal and the tradition is rooted. Peru is the obvious choice for a reason — the Shipibo and mestizo curandero traditions are deep, the infrastructure exists, and the surrounding Amazon is part of the experience. Costa Rica has become a popular middle ground for travelers who want something a bit gentler, more pan-Amazonian or eclectic. Brazil offers the Santo Daime and UDV church contexts, which feel quite different from a jungle retreat. Each setting changes the experience in ways that matter. One practical note: visiting an exotic country during what may be one of the most psychologically intense weeks of your life is its own variable. Some people thrive on the strangeness. Others find it adds noise they didn't need. Be honest with yourself about which one you are. Here's where you become a detective. The marketing language on most ayahuasca retreat sites is interchangeable — "sacred space," "ancient wisdom," "profound transformation." Useless. What you want are the specifics that signal real operational competence. That last one matters more than people like to admit. There have been credible reports over the years of misconduct by facilitators in this scene — predominantly toward women, predominantly during the vulnerable hours of ceremony. A good center has explicit policies, clear reporting channels, and ideally women on staff who can be approached directly. If you can't find any mention of this kind of safeguarding anywhere on the site, ask. The answer will be informative either way. You don't get to choose your ceremony-mates, but the center does. Their screening is your screening. A group of eight to fifteen people who've all been carefully vetted will feel completely different from a group of thirty walk-ins who paid the cheapest price they could find. Group size cuts both ways. Smaller groups (six to ten) tend to feel more intimate and allow more individual attention from facilitators. Larger groups can generate a collective energy that some people find amplifying — the morning sharing circles are richer, the range of experiences more varied. Neither is universally better. Know which one suits your temperament. For people working specifically with sexual trauma, gender-related wounds, or who simply feel safer in single-gender settings, women-only and men-only retreats exist and are worth seeking out. The container is genuinely different, and for the right person it removes a layer of vigilance that would otherwise eat into the experience. The ceremony itself is maybe 20% of the actual work. The dieta beforehand and the integration afterward are where most of the change either takes root or evaporates. A retreat that treats preparation as a formality and integration as an afterthought is selling you a ride, not a process. Real preparation usually means at least two weeks of clean eating — no pork, no fermented foods, no alcohol, minimal sugar, minimal salt, no recreational drugs, no sexual activity in the final stretch for many traditions. It also means sitting with your intentions. Why are you doing this? What are you actually hoping to look at? "I want to heal" is a starting point, not an answer. Get specific with yourself before the medicine gets specific with you. Integration is the long tail. The insights from a ceremony are vivid in week one and slippery by week six. Centers that offer follow-up calls, integration circles, recommended therapists, or community access are doing real work. The ones that just hand you a certificate and a t-shirt are not. None of this guarantees a good experience — ayahuasca is famously its own teacher, and even the best-run retreat can serve up a night that humbles you completely. But choosing carefully tilts the odds. If you're at the stage of seriously comparing options, a range of vetted ayahuasca retreats can be browsed on our marketplace here, which is a reasonable place to start narrowing the field. Take your time with the decision. The plant will still be waiting whenever you're ready.
Ayahuasca and Meditation: Why Both Rewire the Brain in Similar Ways
Picture two scenes. In one, somewhere off a muddy trail in the Peruvian Amazon, a thatched ceremonial house glows with candlelight while an Onanya healer pours a thick, bitter brew into a wooden cup. In the other, a neuroscientist in a Barcelona hospital watches brain scans flicker across a monitor as a volunteer comes down from that very same medicine. Different rooms. Different languages. Oddly similar findings. That's the part that keeps catching researchers off guard. The traits that show up in long-term meditators — the people who've logged thousands of hours on the cushion — are showing up in people who've sat with ayahuasca a handful of times. Openness. Optimism. A particular kind of mental distance from one's own thoughts. For anyone weighing whether a psychedelic retreat could help with depression, addiction, or the kind of stuck thinking that grinds you down for years, this overlap matters. The trait researchers keep pointing to is called decentering. It's a clunky word for something most of us have glimpsed once or twice. Decentering is the ability to watch a thought arise — say, I'm worthless or I'll never get past this — and recognise it as a thought, not as a fact about who you are. You see it. You don't become it. This is one of the explicit aims of mindfulness practice. It's also a documented target of certain evidence-based depression treatments, particularly mindfulness-based cognitive therapy. People who score higher on decentering tend to score lower on measures of anxiety, depression, and unresolved grief. That's not a fringe claim. It's been replicated across plenty of studies of long-term meditators. What's newer is the finding that ayahuasca seems to nudge people toward the same psychological territory — and faster. Volunteers in studies run by groups like the Beckley Foundation report higher decentering scores after ceremony, and those scores track with reductions in depressive symptoms and improvements in overall well-being. The brew, in other words, appears to be giving people a glimpse of a mental skill that monks spend decades cultivating. Surveys can only take you so far. People sometimes report feeling better because they expect to feel better, or because they paid a lot of money to go sit in the jungle and would prefer not to feel like idiots. That's why the neuroimaging work matters. In Barcelona, neurologist Jordi Riba has been scanning the brains of depressed volunteers who've taken ayahuasca. In one small study of seventeen people with depression, scans showed a noticeable drop in activity in brain regions that tend to be overactive in depressed and anxious people — particularly the parts associated with rumination and the constant self-referential chatter that keeps depressive loops spinning. Follow-up work with long-term ayahuasca users has suggested those same regions may actually be physically smaller. The pattern lines up with what David Nutt at Imperial College London has been describing for years. People with depression or addiction, he argues, get locked into patterns of thought driven by the brain's control center — what neuroscientists call the default mode network. Psychedelics seem to temporarily knock that network offline. The mind goes loose. New connections form. And for some people, the rigid loop they've been stuck in for a decade simply opens. Long-term meditators, it turns out, also show quieter default mode networks. Same brain region. Same dampening effect. Two completely different routes to the same neurological neighbourhood. If you've landed on this article, there's a decent chance you're not reading it for the science alone. You're trying to figure out whether a ceremony, or a week-long retreat, or a longer stretch with master plants might actually do something for you. Fair question. Here's what the research above suggests — and what it doesn't. What it suggests: What it doesn't suggest: Ayahuasca isn't alone here. Research out of NYU and Johns Hopkins on psilocybin — the active compound in magic mushrooms — has produced strikingly similar results in people with treatment-resistant depression, end-of-life anxiety, and alcohol use disorder. Ibogaine, used for opioid addiction, appears to interrupt withdrawal and compulsion in ways no pharmaceutical has matched. San Pedro and peyote, both mescaline-bearing cacti, have their own long traditions of use for psychological and spiritual healing. In Amazonian traditions, ayahuasca sits within a broader category called master plants — teacher plants taken under dieta, sometimes for weeks at a time, to address specific physical, emotional, or spiritual issues. It's a framework worth understanding before booking anything. The medicine isn't the whole picture; the relationship between participant, facilitator, plant, and integration is. One useful comparison to chew on: meditation is free, available anywhere, and works — slowly, reliably, for those who commit. Plant medicine is expensive, geographically inconvenient, legally complicated in most countries, and works — sometimes dramatically, for those who commit to the much harder integration work afterward. Neither one is a shortcut. They're different on-ramps to the same territory. If the research above has you genuinely curious rather than just intrigued, a few things worth knowing before you put down a deposit: The reason any of this matters is that the brain changes the research is documenting don't happen in a vacuum. They happen inside a container — the setting, the people, the songs, the silence afterward. Get the container right and the medicine has somewhere to land. Get it wrong and you've spent a lot of money to feel sick in a hut. The most honest thing I can tell you, after years around this work, is that the people who get the most from plant medicine tend to be the ones who didn't arrive expecting it to fix them. They arrived curious. They did the prep. They sat with what came up — pleasant or otherwise — and then they kept doing the work once they got home. Meditation, therapy, journaling, time with people who knew them before. The retreat was the doorway, not the destination. The science is catching up to what Amazonian traditions and contemplatives have been saying for a long time: there's more than one way to quiet the noisy part of the mind that's been making you miserable. Some people find it on a cushion. Some find it in a maloca at three in the morning. For readers who want to take this further, a range of curated ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you choose, choose it with your eyes open.
Florida's Legal Mushroom Dispensary: What Amanita Muscaria Actually Is
Walk into a small storefront in Tampa and you can buy psychedelic mushrooms over the counter. Legally. No prescription, no clandestine handoff, no Telegram chat with a stranger named Mushroom_Mike. Just gummies, capsules, and powders sitting on a shelf next to the hemp flower. Sounds like the headline every psychedelics watcher has been waiting for, right? Not quite. The mushrooms in question aren't the psilocybin variety that's been making waves in clinical trials and ayahuasca-adjacent retreat conversations. They're Amanita muscaria — the red-capped, white-spotted toadstool you've seen in Mario games and fairy-tale illustrations your whole life. And the legal loophole keeping this shop open says a lot about where psychedelic culture in the U.S. actually stands right now. The dispensary, run by a longtime cannabis activist who cut his teeth fighting for medical marijuana in Florida, started life as a hemp shop in 2018. Mushrooms got added to the product mix more recently. The owner is careful with his language — he doesn't call them “magic” mushrooms in the store, because that word is shorthand for psilocybin, and psilocybin is firmly Schedule I under federal law. Same legal tier as heroin. Possession alone can wreck your life. What he sells instead is Amanita muscaria, a mushroom that's psychoactive but contains no psilocybin. Its active compounds are muscimol and ibotenic acid — different chemistry, different experience, and crucially, not scheduled by the DEA. Federally, it's legal. State-by-state it's legal almost everywhere, with Louisiana being the lone exception. That's the loophole the whole shop hinges on. The product range includes capsules, gummies, powdered extracts, and even mycology kits — the kind you could, in theory, use to cultivate something more potent. Buyers sign a form swearing they won't. Whether anyone actually believes the form does much is another question. This is the part most casual readers miss, and it's the part that matters most if you're researching plant medicine seriously. Amanita muscaria and psilocybin mushrooms are not interchangeable. They're not even close. Psilocybin works on serotonin receptors — the same neighborhood ayahuasca's DMT visits, the same neighborhood LSD and mescaline operate in. The classic psychedelic family. Amanita muscaria, on the other hand, works on GABA receptors via muscimol. The experience people describe is more dissociative, dreamlike, often sedating — sometimes nauseating, sometimes confusing, occasionally just unpleasant. It's been used ritually for centuries in Siberia and parts of Northern Europe, but it never built the kind of therapeutic case study record that psilocybin has. Here's the other thing nobody puts on the gummy label clearly enough: raw Amanita muscaria is toxic. Eat one off the forest floor and you can end up vomiting, hallucinating in distressing ways, or — in rare but documented cases — comatose. The Tampa shop's owner says he sources from Lithuania and processes the mushrooms to reduce ibotenic acid before they reach the shelf. That's standard practice for traditional preparation. It's also entirely dependent on the seller doing it right. The shop owner isn't naive about what he's doing. He hired a lawyer before stocking the product. He notified local law enforcement. His read is straightforward — drugs get banned when they become a public problem, and Amanita muscaria has flown under the radar for decades because almost nobody was using it. The moment it becomes popular, he expects pushback. He's probably right. There's already a quiet pattern of regulators reacting to legal-gray-area substances once they hit critical mass. Kratom, Delta-8 THC, kava bars — every one of them went through a window of accessibility followed by a patchwork of state-level restrictions. Amanita products are next in line if sales scale up. Meanwhile, the broader landscape for psychedelics is shifting in ways that make this Florida experiment look almost quaint: What's happening in Tampa isn't the leading edge of psychedelic policy reform. It's a side door — one entrepreneur testing how much legal weight a technically-legal mushroom can hold. Let's say you read about this and thought, “Huh, maybe I should try an Amanita gummy.” Pause for a second. People researching plant medicine seriously — for depression, addiction, trauma, the stuck-life-pattern stuff most readers are quietly carrying — generally aren't looking for a novelty trip. They're looking for something with a track record. And Amanita muscaria's track record in modern healing contexts is thin. There's traditional Siberian shamanic use, sure. There's anecdotal hobbyist reporting online. There's not much in the way of contemporary therapeutic research, integration frameworks, or experienced facilitators working with it in retreat settings. Compare that to ayahuasca, which has decades of formalized ceremonial structure in the Amazon, a growing body of neuroscience research, and an established retreat infrastructure with facilitators who've sat with hundreds or thousands of participants. Compare it to psilocybin, which is moving through clinical trials and into legal regulated programs. Compare it to ibogaine, which has a niche but well-documented role in interrupting opioid addiction. Amanita doesn't sit in that conversation yet. It might one day. Right now it doesn't. That doesn't mean it's worthless — it means if you're spending money and intentional time on a psychedelic experience aimed at real change, an Amanita gummy from a Florida shop is probably not the tool. A properly run retreat with a tradition behind it almost certainly is. The Tampa dispensary matters less for what it sells and more for what it represents — the cultural appetite for legal access to psychedelics is way ahead of the legal framework. People are walking into a storefront in a state where recreational cannabis is still illegal and buying mushroom gummies. The demand is here. The infrastructure is improvising around the law. That improvisation comes with real risk. Unregulated processing means quality varies wildly. Lack of guidance means people take these substances alone, with no preparation, no integration, no one watching out for them if the experience gets difficult. The retreat model — for all its costs and complications — exists precisely because psychoactive experiences benefit enormously from container, intention, and skilled support. A gummy in your apartment doesn't offer any of that. If you've been reading about psychedelics and feeling the pull toward something deeper than a curious experiment, the better question isn't where can I buy this legally. It's what am I actually hoping to address, and what tradition or modality has the strongest track record for it. For some people that's psilocybin in Jamaica or the Netherlands. For others it's ayahuasca in Peru or Costa Rica. For people working with opioid addiction it might be ibogaine in Mexico. The match matters more than the convenience. For readers who want to take this further, a range of curated ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly — these aren't gummies you grab on a whim.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Aaron Rodgers and Ayahuasca: What His Plant Medicine Journey Tells Us
A few years back, when Aaron Rodgers casually mentioned on a podcast that he'd done ayahuasca twice in Peru and considered it one of the most meaningful experiences of his life, the sports internet did what the sports internet does. It made memes. It clutched pearls. It treated the whole thing as another item in the quarterback's growing catalogue of weird wellness choices, somewhere between the hyperbaric chamber and the dolphin-sex-sounds rumour. But if you're someone actually considering a plant medicine retreat — and if you've landed here, there's a decent chance you are — Rodgers' very public arc through ayahuasca, psychedelics, and master plants is worth a closer look. Not because a Super Bowl ring makes him an authority on consciousness. It doesn't. But because his story illustrates something the broader conversation around psychedelic healing keeps bumping into: high-profile people are using these medicines, they're talking about the results, and a lot of regular folks are quietly wondering whether they should too. So let's sort the signal from the noise. What did Rodgers actually do? What does the research say about ayahuasca and psychedelics for the kinds of issues he described — anxiety, identity questions, addiction-adjacent patterns? And if any of this resonates with where you are right now, what would a thoughtful path forward actually look like? In interviews with Aubrey Marcus and others, Rodgers described two ayahuasca ceremonies in Peru that he framed as the source of his back-to-back MVP seasons — though he was careful to say the medicine wasn't a performance enhancer in any direct sense. What it did, in his telling, was help him love himself more fully, soften the inner critic, and reconnect with what he called "unconditional love." That language gets eye-rolls from people who haven't sat with the medicine. Which is fair. It sounds like the kind of soft-focus retreat brochure copy that any reasonable adult would mock. But here's the thing: it's also a pretty accurate, if compressed, description of what a lot of people report after a well-held ayahuasca ceremony. The vocabulary is limited. The experience isn't. Rodgers also talked about the difficulty of the ceremonies themselves — purging, confronting fear, sitting with old material from childhood and earlier relationships. He didn't paint it as a vacation. He painted it as work. And that, more than anything, is the part of his account worth trusting. Ayahuasca is a brew traditionally prepared in the western Amazon — Peru, Ecuador, Colombia, Brazil — by combining the Banisteriopsis caapi vine with the leaves of Psychotria viridis (or a similar DMT-containing plant). The vine contains MAO inhibitors that allow the DMT in the leaves to become orally active. Drink it on its own and your body breaks the DMT down before it does anything. Drink them together and you get a four-to-six-hour experience that participants often describe as the most psychologically intense thing they've ever done. Indigenous groups have used the brew for centuries — possibly much longer — for healing, divination, and what's often translated as "soul retrieval." In the lineages that take it seriously, ayahuasca is considered a master plant: a teacher, not a drug. That framing matters. It's not a recreational substance and it's not designed to feel good. It's designed to show you what you've been avoiding. Modern research is still early but increasingly serious. Studies out of Brazil, Spain, and the U.S. have looked at ayahuasca's effects on depression, PTSD, and substance use disorders. The results aren't a cure-all, but they're consistent enough that organizations from Johns Hopkins to Imperial College London are watching the space closely. This is where Rodgers' story gets more interesting, and where the science is moving fastest. The quarterback hasn't publicly described an addiction in the clinical sense, but he's been open about cycles of self-criticism, family estrangement, and the kind of psychological loops that anyone in recovery would recognise. The research on psychedelics for addiction is some of the most promising work in mental health right now. A few highlights worth knowing about: The mechanism isn't fully understood, but the working theory goes something like this: addictions are often rigid patterns of avoidance — ways of not feeling something. A high-dose psychedelic experience temporarily dissolves the defensive structures that keep those patterns in place, and a few hours of honest contact with what's underneath can reset something that years of talk therapy couldn't budge. That's the optimistic version. The honest caveat: psychedelics don't do the work for you. They open a door. You still have to walk through it, and you still have to live differently when the ceremony ends. The people who get lasting benefit are almost always the ones who took integration seriously — meaning therapy, community, lifestyle changes, sometimes for years after. If Rodgers' account has made you curious enough to look into a retreat yourself, a few practical things to know before you start clicking through websites. A reputable ayahuasca retreat is not a wellness vacation. It's typically four to ten days, often in a remote part of Peru, Costa Rica, or Brazil, with two to five ceremonies held overnight. The days between ceremonies involve a strict diet (no salt, sugar, pork, alcohol, sex — the famous dieta), conversations with facilitators, and a lot of unstructured time for reflection. You will probably be uncomfortable. You will almost certainly purge. You may not enjoy yourself in the conventional sense. Things to look for when evaluating a retreat: Ayahuasca gets the headlines, but it's one tradition among several. Rodgers has hinted at curiosity about other plant medicines, and the broader field is rich: San Pedro (huachuma) is a cactus from the Andes containing mescaline. The experience is longer than ayahuasca — often twelve hours — and many people describe it as gentler, more heart-centred, less confrontational. It's often used for grief, relationship work, and reconnecting to the natural world. Psilocybin mushrooms are increasingly available in legal retreat settings in Jamaica, the Netherlands, and Oregon. They tend to be more visually rich and somewhat more predictable in dose than ayahuasca, which makes them appealing for first-time journeyers. Ibogaine is the heavyweight for opioid addiction specifically. It's also the most medically risky of the major plant medicines — it can affect heart rhythm — and should only be approached in clinics with cardiac monitoring. None of these are interchangeable. Choosing one over another isn't a matter of preference so much as fit — what you're working with, what your medical history allows, and what tradition speaks to you. Aaron Rodgers will believe what he believes about wellness, and a chunk of his catalogue — the dolphin sounds, the ivermectin, the diluted virus story — falls somewhere between unproven and actively concerning. But ayahuasca isn't in that pile. The plant has a centuries-deep lineage, a growing body of clinical research, and a generation of regular people quietly reporting that it helped them with things nothing else touched. If you're sitting with depression, addiction, trauma, or the specific kind of stuck-ness that no amount of journaling seems to crack — psychedelic healing is worth knowing about. Not as a silver bullet. As one tool, used carefully, in the right setting, with the right people, followed by months of real integration work. For readers who want to take this further without wading through a hundred sketchy websites, a curated range of ayahuasca and plant medicine retreats can be browsed on our marketplace here. Whatever you choose, choose slowly. The medicine isn't going anywhere, and the decision deserves the same seriousness as the experience itself.
Ayahuasca and Nature: What an Amazonian Retreat Actually Does to Your Mind
There's a moment, somewhere around the third or fourth ayahuasca ceremony, when people start saying odd things. Not visionary things — those come earlier. I mean the quiet remarks at breakfast about a particular tree, or the way someone keeps drifting back to the same stretch of riverbank between ceremonies. Something has shifted in how they're seeing the place. For years, this kind of report sat in the anecdotal pile. Trip stories. Integration journals. The sort of thing you hear at a retreat but rarely see written up in a journal with proper statistics attached. That's begun to change. A pilot study published in Drug Science, Policy and Law looked at exactly this question — does sitting with ayahuasca in the Amazon actually change a person's felt connection to nature? — and the answer, with the usual caveats, appears to be yes. The team followed 43 participants through an Indigenous-led ayahuasca retreat at the Ayahuasca Foundation, a center deep in the Peruvian Amazon. The ceremonies were conducted in an adapted Shipibo format, led by Indigenous shamans, with participants attending anywhere from four to eleven ceremonies over stays that ranged from ten days to a full month. The average person sat in roughly six ceremonies. Before their first ceremony and the morning after their last, participants filled out a set of standardized inventories. Two measured what psychologists call “nature relatedness” — essentially, how deeply you feel woven into the natural world rather than separate from it. The other measured depression, anxiety, and stress. Nothing exotic about the instruments. These are the same scales used in plenty of mainstream psychology research. What makes this study slightly unusual isn't the methodology. It's the setting. Most psychedelic research happens under fluorescent lights in clinical rooms. This one happened in a maloca surrounded by jungle, with no cell service, limited electricity, and the constant hum of insects and frogs as the soundtrack to every ceremony. Three things moved significantly between pre- and post-retreat measurements: One thing didn't move: anxiety. Scores on the anxiety subscale were essentially flat. The researchers offer a reasonable explanation — being at a remote jungle retreat, away from everything familiar, drinking a brew that has a reputation for being intense, is itself an anxiety-provoking situation. The questionnaire was asking about the past week, and the past week included some genuinely nerve-rattling experiences. So a null result there isn't really a failure; it's an honest read of the environment. The more interesting finding is the correlation between the changes. People whose nature relatedness rose the most also tended to be the ones whose stress dropped the most. That link held up statistically. Whatever was shifting in their relationship to the natural world seemed tied to what was shifting in how their nervous system felt. This is the question that always hangs over plant medicine research, and it's the right one to ask. Sit in a maloca for two weeks with no phone, no email, eat plain food, follow a strict dieta, fall asleep listening to monkeys — of course you're going to feel more connected to nature. You'd probably feel that way without drinking anything. The researchers are careful about this. They don't claim ayahuasca alone is doing the work. They lay out the obvious confounders: So yes, context matters. A lot. But there's also evidence from controlled laboratory studies, where people drink psilocybin or LSD under sterile clinical conditions with no jungle in sight, showing similar shifts toward nature relatedness afterward. That suggests the molecule itself is doing something, even when stripped of every romantic setting. The honest answer is probably that both the plant and the place are pulling in the same direction, and at a real retreat they amplify each other. If you're reading this because you're considering a retreat for depression, addiction, or just being stuck — the nature-relatedness angle might sound like a sideshow. It isn't, and here's why. Decades of environmental psychology research has tied higher nature relatedness to better emotional regulation, more psychological resilience, more reported vitality during stressful periods, and greater overall well-being. People who feel embedded in the natural world appear to have a sturdier nervous system on average. They cope better. They report more meaning. They're less likely to spiral. So when an ayahuasca retreat produces a measurable jump in this trait — and that jump correlates with a drop in stress — it's pointing at something potentially important. It suggests the mental-health benefits people report after plant medicine aren't only about resolving specific traumas or breaking specific patterns. Part of the benefit may come through this slower, more ambient shift in how a person locates themselves in the world. Less alone. More part of something. Less convinced that the planet is wallpaper for human drama. One researcher cited in the paper argues that maximizing nature relatedness during psychedelic administration may be an underrated path to better outcomes. If that's true, the implications for retreat design are interesting. The jungle setting isn't decorative — it might be load-bearing. A pilot study with 43 participants and no control group can't prove much on its own. The researchers are upfront about this. But if you're weighing whether to spend the money and the time on an Amazonian retreat versus, say, a weekend ceremony closer to home, the findings are worth chewing on. A few honest takeaways: What I find interesting about studies like this isn't the headline finding — most people who've sat with ayahuasca already suspected something like this was happening. It's that the research community is finally taking the phenomenology seriously enough to measure it. For a long time, the visionary content of these experiences was treated as noise. Side effects. Pretty wallpaper around the “real” pharmacological action. Slowly, that view is shifting. The content of the experience — the trees, the river, the songs, the feeling of being held by a living world — might be part of the active mechanism, not a distraction from it. That has implications well beyond retreats. It hints at why nature-based mental health interventions, forest bathing protocols, and even time spent gardening keep showing measurable benefits in trials. Plant medicines may be working on the same neural and psychological circuitry, just turned up to eleven. None of this is a green light to book the first retreat that pops up in your search results. Quality of facilitation, screening for contraindications, integration support, and the ethics of how Indigenous knowledge is being used all still matter enormously. Ayahuasca isn't a vacation, and the centers running responsible operations look meaningfully different from the ones running tourist mills. If something here speaks to you, the ayahuasca retreats discussed across this broader Amazonian tradition can be browsed and booked on our marketplace here. Take your time with the decision. The jungle isn't going anywhere, and the question of whether to drink the vine deserves a slower yes than most things in your life right now.
Best Ayahuasca Retreats in 2026: An Honest Guide for First-Timers
Ayahuasca has been working its way out of the Amazon for a long time. What was once the closely held practice of Shipibo, Shuar, and other Amazonian lineages is now available — for better and worse — on five continents. If you're reading this, you're probably weighing whether to actually go. Maybe you've been circling the idea for months. Maybe a friend came back from Peru looking different and you can't stop thinking about it. This piece is for that person. Not a hype reel. A working list of ayahuasca retreats that have earned reputations for taking the medicine — and the people who drink it — seriously. I'll tell you what each one does well, who it tends to suit, and roughly what it costs. The rest is your call. Ayahuasca is a brew. Two plants, usually: the Banisteriopsis caapi vine and a DMT-containing leaf (most often chacruna). Cooked together for hours, sometimes days. The vine contains MAO inhibitors that let the DMT become orally active. Without that pairing, you'd just have a bitter tea and a stomachache. What it does to you is harder to summarize. People describe vivid visions, deep emotional release, encounters that feel like meetings with something other than themselves. Many also describe vomiting, sweating, and several hours of intense discomfort. Both are normal. The Amazonian traditions consider ayahuasca a teacher — one of the master plants — and the work is to listen, not to perform. It's not a recreational drug. It's not a guarantee of healing. And it doesn't care about your itinerary. Going in with that humility tends to produce better experiences than going in expecting fireworks. Before the list, the criteria. After interviewing a fair number of facilitators and sitting in a handful of ceremonies, here's what I'd want to know before booking anywhere: Price is the last filter, not the first. A cheap retreat with sloppy screening can cost you a lot more than a careful one. Soltara built its reputation by pairing Shipibo maestros with a Western-trained support team, and it shows in the small things — the screening process, the integration calls, the careful pacing of ceremonies across a week. Accommodation runs from shared to private, and the food is the kind of thoughtful that makes the post-ceremony day less brutal. A solid first choice for someone who wants traditional ceremony without roughing it. From around $2,225 for a five-day retreat. Small groups — under ten — and a four-month integration program after you leave. That last detail is what sets Anam Cara apart. Most centers wave you off at the airport. This one keeps showing up. Shipibo maestros lead the ceremonies; an on-site psychotherapist and a somatic practitioner support the daytime work. From $3,900 for eight days. Co-founded by a psychologist who's spent nearly three decades in this work. Spirit Vine grows its own ayahuasca on the property, which is unusual and worth mentioning — you know exactly what you're drinking. The setting is jungle bungalows with serious views, the food is vegan, and the ceremonies blend shamanic technique with Western psychological framing. From $2,250 for nine days. Forty-two acres in the Amazon basin, traditional Shipibo ceremonies, and lifestyle coaching layered over the top. Hummingbird tends to attract people working on entrenched patterns — the medicine surfaces the belief, the coaching helps you do something about it once you're home. From $2,200 for nine days. Trauma-aware from the ground up. The facilitation team includes coaches and psychotherapists trained in trauma work, paired with Amazonian healers who actually live and study in Ecuador and Peru. They occasionally bring in Maestro Pepe — the curandero featured in the Netflix documentary The Last Shaman. A good fit for first-timers and for people who've done some therapy and want a container that respects the nervous system. From $2,373 for seven days. The customizable option. You can join a Yawanawá group ceremony for a few hundred dollars or build a private retreat with a partner at an eco-resort. The flexibility makes it accessible to people whose budgets don't stretch to a $3,000 week. Group ceremonies start around $225; private retreats are quoted individually. Europe's most established ayahuasca container, run by therapists, doctors, and curanderos trained in Colombian, Peruvian, and Brazilian lineages. Avalon also offers bufo (5-MeO-DMT) and kambo sessions if you're curious about the wider plant-medicine landscape. From €1,950 for four days. Four decades of operating experience and on-site medical support, including a GP, a psychologist, and a shaman. Etnikas is the place I'd quietly recommend to a nervous first-timer who wants Peru without committing to two weeks in the deep Amazon. An hour from Cusco, two from Machu Picchu. From $625 for three days. Small groups, multidisciplinary facilitators (psychology, physiotherapy, hypnotherapy), and integration that's treated as the actual point. Portugal's southern coast in the off-season is gentle weather for nervous-system work. From €780 for a weekend with two ceremonies. On the beach. Literally on the beach. Ceremonies happen with the Pacific in earshot, and the supporting modalities — family constellation work, sound healing, breathwork — are unusually thoughtful. If the jungle feels too intense and you want the ocean as your container instead, this one's worth a look. From $2,590 for nine days. Private retreats only, for individuals or couples. Three ceremonies structured around the Anaconda, Jaguar, and Condor archetypes, plus one-on-one energy work and access to off-site spa amenities. Suited to people who, frankly, don't want to share their breakdown with eleven strangers. From $3,850 for eight days. The most affordable option on this list that still feels legitimate. Ecuadorian shamans, mountain air, simple but comfortable accommodation with hot showers and decent food. A good gateway for younger travelers or anyone whose finances aren't going to stretch to the $3,000+ centers. From $1,050 for six days. Two locations, one in the Amazon and one in the Sacred Valley. Arkana is an eco-lodge first, meaning the physical container is well-built and easy to live in for a week. Ceremonies are Shipibo-led and the integration program is structured rather than improvised. Hard to describe without sounding either ridiculous or dismissive. Here's the honest version. Around forty minutes after you drink, the curandero starts singing icaros — the medicine songs — and your body starts shifting in ways you've never quite felt before. You might purge. You probably will, at some point across the week. The visions, when they come, don't feel like a movie playing in front of you; they feel like meetings. Sometimes with people you've lost. Sometimes with a part of yourself you've been avoiding. Sometimes with something the Amazonian traditions would call a spirit and Western psychology would call the unconscious. The labels matter less than you'd think. It usually lasts four to six hours. Toward the end you'll be exhausted and weirdly clear. Sleep doesn't come easy. The next day you'll feel like you ran a marathon emotionally, and the day after that you might feel better than you've felt in years. Or worse, briefly, before things settle. Both are part of it. Ayahuasca isn't safe for everyone. If you take SSRIs, MAOIs, or certain other psychiatric medications, the combination can be dangerous and a responsible center will require a taper supervised by a doctor. If you have a personal or family history of bipolar disorder or schizophrenia, most reputable centers will turn you away — and you should be wary of any that don't. Certain heart conditions are absolute contraindications. Even for people who clear the screening, this is hard work. The marketing language around plant medicine sometimes makes it sound like a spa weekend with extra meaning. It isn't. It's closer to surgery on parts of yourself you've kept hidden, often for good reasons. Going in prepared — with intentions written down, a plan for after, and people at home who know what you're doing — is how this medicine pays off. Going in casually is how people get hurt. Integration is the whole game. The insights you receive in a ceremony are vivid in the moment and weirdly slippery a week later. Without structure, they fade into a nice story you tell at dinner parties. With structure, they become actual changes. What integration looks like in practice: regular contact with a facilitator or therapist for at least a few months, journaling the specifics of what came up, small concrete commitments to behavior change, and ideally a community of other people who've done this work. The centers that build this in — Anam Cara, APL, Vine of the Soul among them — tend to produce better long-term outcomes than ones that send you home with a hug and a hope. If you're seriously considering this path — for addiction, for depression, for trauma, or for something you can't quite name yet — take your time choosing where to go. Read reviews on multiple platforms. Email the centers and see how they respond. For readers who want to take this further, a curated selection of ayahuasca retreats from many of the lineages discussed above can be browsed on our marketplace here. Whatever you decide, decide it slowly. The medicine will still be there next year.
Psilocybin Mushrooms Explained: Effects, History, and What Retreats Actually Offer
Psychedelic mushrooms have been sitting at the strange intersection of ancient ritual and modern neuroscience for longer than most people realise. They show up in cave paintings from the Sahara. They show up in clinical trials at Johns Hopkins. And lately, they show up in conversations between people who never thought they'd consider plant medicine at all — quiet conversations about depression that won't budge, grief that won't move, or a relationship with alcohol that's stopped being funny. If you're researching psilocybin because you're weighing whether to sit with these mushrooms — alone, with a friend, or at a proper retreat — this guide is for you. We'll cover what these fungi actually are, where they come from, what the experience tends to feel like, and how psychedelic healing has become part of a broader return to master plants and plant medicine. No hype. No promises. Just the kind of detail you'd want from a friend who's done the reading and sat in a few ceremonies. The umbrella term “magic mushroom” covers more than 180 species of fungi spread across every continent except Antarctica. What ties them together is a single compound: psilocybin. When you eat the mushroom, your body converts psilocybin into psilocin, and psilocin is what binds to serotonin receptors in the brain — specifically the 5-HT2A receptor — and produces the experience people call a trip. Most of the well-known species belong to the genus Psilocybe. You'll hear names like Psilocybe cubensis (the famous “golden teacher” or cubes), Psilocybe semilanceata (liberty caps, the small pointy ones that pop up in damp British fields), and Psilocybe azurascens, which is widely considered the most potent species in the wild. For perspective: azurascens contains roughly 1.78% psilocybin by dry weight, while cubensis usually clocks in around 0.63%. That's nearly a threefold difference in punch. One thing worth flagging hard, especially for the curious forager: several psilocybin species have deadly lookalikes. The mycologist Paul Stamets has written at length about how easily Psilocybe cyanescens, for instance, can be confused with Galerina marginata, which can kill you. This isn't fearmongering — it's the reason serious people either grow their own, source carefully, or go to retreats where someone qualified is handling dosing. People have been eating these mushrooms for a very long time. In the Tassili-n-Ajjer region of the Algerian Sahara, there's a 7,000-to-9,000-year-old rock painting of a bee-headed figure with mushrooms sprouting from his body. Scholars believe the depicted species is Psilocybe mairei, which still grows in the area. There's a similar mural in Spain — the Selva Pascuala painting, about 6,000 years old — showing what look like Psilocybe hispanica caps in a row. In Mesoamerica, the evidence is even denser. Stone carvings of mushroom-shaped figures from Mexico and Guatemala date back to roughly 1,500 BC. The Maya consumed what they called k'aizalaj okox. The Aztecs called them teonanácatl — “flesh of the gods” — and used them in ceremonies involving honey, chocolate, music, and an entire night of singing, weeping, and visions. A Spanish missionary, Bernardino de Sahagún, documented these gatherings in the 1500s, mostly with the disapproving tone you'd expect from a 16th-century friar. The modern West more or less ignored all of this until 1955, when an amateur mycologist named R. Gordon Wasson travelled to Oaxaca and sat in a velada ceremony with the Mazatec curandera María Sabina. He wrote about it for Life magazine two years later, and the world's curiosity cracked open. By 1958, Albert Hofmann — yes, the same chemist who'd synthesised LSD — had isolated psilocybin and psilocin in his Swiss laboratory. Within a decade, the molecule was in academic journals, then in the counterculture, then in the legal crosshairs. This is the question most people really want answered, and it's also the hardest. The honest answer: it depends on the dose, your nervous system, the setting, and the intention you bring in. At a low dose (roughly 0.5 to 1.5 grams of dried cubensis), most people report a softening of the visual field, a sharpening of music, mild emotional warmth, and a tendency to find everything slightly funnier than usual. At a moderate dose (around 2 to 3.5 grams), things get more pronounced — geometric patterns when you close your eyes, time dilation, intense feeling-states that move through you like weather, and the sense that you can see your own patterns from the outside. At a high dose (3.5 grams and up, sometimes called a “heroic dose”), the experience can dissolve the sense of self entirely, which is the territory where the deepest psychedelic healing — and the most genuinely difficult moments — tend to happen. What people who've sat in ceremony tend to describe more than visuals, though, is the emotional clarity. The thing you've been avoiding for fifteen years walks into the room and sits down across from you. The conversation you've been rehearsing with a dead parent finally happens. The grip of a craving softens for a few hours, and you remember what you actually want from your life. None of that is guaranteed. Some sessions are quiet. Some are confusing. A few are frankly hard. That's the deal you're signing when you sit with these mushrooms. This is where the recent research has been most striking. Clinical trials at Johns Hopkins, NYU, and Imperial College London have produced findings that would have sounded like science fiction twenty years ago: a single high-dose psilocybin session, paired with proper therapy, has helped a significant percentage of long-term smokers quit, treatment-resistant depression patients enter remission, and alcohol-use disorder patients reduce drinking sharply. The numbers aren't perfect and the trials are small, but the signal is consistent enough that the FDA has designated psilocybin a “breakthrough therapy” for depression. Why does it work, when it works? The current theory — and it is still a theory — is that psilocybin temporarily loosens the brain's default mode network, the system that holds together your sense of self, your habits, and your stories about who you are. In that loosened state, you can examine patterns that normally feel fixed, including addictive ones. Then, in the weeks after, while the brain is more neuroplastic than usual, integration work helps the insights actually stick. That last part is what most people underestimate. The mushroom does not heal you. What you do in the month after the mushroom — therapy, journaling, sleep, honest conversations, behavioural changes — is what determines whether anything actually shifts. Skipping the integration is the single most common reason people walk away from a powerful experience and find themselves, six months later, exactly where they started. Short version: in most countries, no. Long version: it's changing fast, and the map gets redrawn every year. If you're seriously considering a retreat, the legal jurisdiction matters less than the quality of the people running it. A licensed Dutch truffle retreat with weak facilitators is a worse bet than a Jamaican mushroom retreat with experienced ones. A few honest questions to sit with before you book anything: Psychedelic mushrooms are not a shortcut, and anyone selling them as one is either inexperienced or dishonest. What they can be — for the right person, in the right setting, with the right support — is a powerful catalyst inside a larger process of paying attention to your own life. The mushroom opens a door. Walking through it, and then living differently on the other side, is on you. If something here is pulling at you and you'd like to see what's actually available, a curated selection of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with the choice — this is the kind of decision that rewards patience.
Psilocybin as Medicine: Why Top Researchers Want Magic Mushrooms Rescheduled
Somewhere between the headlines about microdosing CEOs and the cautious clinical trials happening at major universities, a quieter shift has been underway. A group of psychiatrists — the kind of people who measure their words and footnote their claims — have spent years arguing that psilocybin, the active compound in magic mushrooms, doesn’t belong on the same regulatory shelf as heroin. Their case is built on data, not vibes. And for anyone weighing whether psychedelic healing is a real option or a fashionable detour, it’s worth understanding what they’ve actually said. The argument boils down to this: psilocybin shows a low risk of harm, a low potential for abuse, and a genuinely meaningful therapeutic ceiling. When researchers at Johns Hopkins University and the University of Alabama at Birmingham reviewed the evidence in the journal Neuropharmacology, they concluded that psilocybin’s original Schedule I classification was based on a substantial overestimation of its dangers. That’s a quiet sentence with loud implications. The paper — co-authored by Matthew Johnson, Roland Griffiths, Jack Henningfield, and Peter Hendricks — makes a specific regulatory claim. They want psilocybin placed in Schedule 5, the most lenient federal category, the same drawer that holds cough syrup with codeine and certain sleep aids. Not legalized for recreational sale. Not unleashed on the corner pharmacy. Made legally available through clinicians, pending the results of ongoing clinical trials. To be in Schedule I, a substance must meet three criteria: high abuse potential, no accepted medical use, and a lack of safety even under medical supervision. The authors point out that the first criterion looks questionable when you examine survey data, and the third is almost certainly false given the safety record of supervised clinical trials. The middle criterion — accepted medical use — is the one currently moving, study by study. This isn’t a fringe position dressed up in academic language. It’s the considered view of researchers who’ve run some of the most rigorous psilocybin trials in the modern era. When people who spend their careers cautiously interpreting fMRI scans use the phrase scientifically based conclusions to describe psilocybin’s therapeutic promise, that’s worth paying attention to. The most-cited piece of work in this conversation is a 2016 clinical trial out of Johns Hopkins, published in the Journal of Psychopharmacology. In it, patients facing terminal cancer diagnoses received a single high dose of psilocybin in a supportive clinical setting. The results were striking enough that Griffiths, in a press call afterward, compared the effect on depression and anxiety to a surgical intervention. One dose. Months of relief for many participants. That kind of effect size is rare in psychiatry, where incremental improvement is usually the headline. The picture has only filled in since. Studies have looked at psilocybin for treatment-resistant depression, obsessive-compulsive disorder, alcohol use disorder, and the existential distress that comes with serious illness. Parallel research on MDMA for PTSD and ketamine for severe depression has reinforced a broader pattern: certain compounds, used carefully, can produce changes that conventional pharmacology has struggled to match. None of this is a miracle cure. All of it suggests we’ve been leaving useful tools in a locked cabinet for the wrong reasons. Surveys of recreational users have added another data point. When researchers compare emergency-room visits and dependency rates across substances, psilocybin consistently ranks among the safest. That doesn’t mean it’s without risk — set, setting, dose, and the person taking it all matter enormously — but it does mean the regulatory framing has been out of step with the physical reality. Skeptics will note that the Drug Enforcement Administration has not been in a rush to reclassify psychedelic compounds. But there’s a precedent worth knowing about. When the FDA approved Epidiolex, a CBD-based medication for two rare forms of epilepsy, the DEA had no choice but to reschedule that specific compound. As a DEA spokesperson put it at the time, the agency doesn’t have a choice once a drug clears FDA approval — it has to move to Schedule 2, 3, 4, or 5. CBD ended up in Schedule 5, the same place the Hopkins authors argue psilocybin belongs. The pathway, in other words, runs through clinical trials. If a pharmaceutical formulation of psilocybin clears the FDA — and several programs are aiming squarely at that goal — federal rescheduling follows mechanically. Some analysts have suggested that approval could come within the next few years, though timelines in drug development are famously elastic. What’s no longer in doubt is the direction of travel. Here’s the part where the policy debate meets the reader’s actual decision. If you’re researching a psilocybin or ayahuasca retreat right now, you’re not waiting for the FDA. You’re weighing whether to fly to a jurisdiction where these experiences are legal or culturally sanctioned, sit with experienced facilitators, and do the work people have been doing in ceremonial settings for a very long time. The science is catching up to something traditional cultures have understood for centuries, and many people who explore plant medicines aren’t willing to wait another five years for a prescription pad. That’s a legitimate choice — but it requires more diligence, not less. A clinical trial gives you a controlled dose, screened mental-health history, and trained psychiatrists in the room. A retreat gives you something different: typically a ceremonial container, often a group of strangers, sometimes deep traditional knowledge, sometimes a slick rebrand of it. The variance between retreat centers is enormous. Some operations are run by experienced facilitators with medical screening and aftercare protocols. Others are weekend businesses with a candle and a playlist. If you’re going this route, ask hard questions before you book. What’s the screening process? Are there contraindications they check for — SSRIs, cardiovascular issues, personal or family history of psychosis? Who’s in the room during the experience? What does integration support look like in the weeks after? A retreat that bristles at these questions isn’t the one you want. The interesting thing about the current moment is that the clinical research and the retreat-based traditions are converging on the same conclusions from opposite directions. Hopkins-style researchers talk about set and setting, integration, and the importance of the therapeutic relationship — concepts that traditional curanderos and ayahuasca facilitators have organized their entire practice around for generations. Master plants, the term used in Amazonian traditions for teacher species like ayahuasca, San Pedro, and tobacco, aren’t just delivery mechanisms for active compounds. They’re embedded in a relational practice that the clinical trials are quietly rediscovering. For someone considering plant medicine to address addiction, depression, trauma, or a stuck pattern in life, both worlds offer something. The clinical pathway offers safety, measurement, and eventually insurance coverage. The retreat pathway offers access now, a depth of ceremonial knowledge that no double-blind study can replicate, and a long lineage of people who’ve done this work. Neither is automatically better. Both have failure modes. The researchers calling for psilocybin to be made medically available aren’t saying psychedelics are safe in a vacuum. They’re saying the supervised, intentional use of these compounds — the kind of use that good retreats and good clinics both aim for — has been miscategorized for fifty years. If something here has caught your attention, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here, and it’s a reasonable place to start comparing what’s actually on offer. None of this is a green light to throw yourself at the nearest ceremony. Psilocybin is not appropriate for everyone. People with personal or family histories of schizophrenia, bipolar disorder, or psychotic episodes should be particularly cautious, and reputable facilitators will screen for these. Certain medications — particularly SSRIs and MAOIs — interact in ways that range from blunting the experience to becoming genuinely dangerous. Cardiovascular conditions deserve a real conversation with a real doctor. And there’s the experience itself, which can be difficult in ways glossy retreat brochures rarely emphasize. Challenging sessions are common. People cry, vomit, confront uncomfortable memories, lose track of time, and sometimes leave a ceremony shaken before the integration process starts to make sense of what happened. The healing, when it comes, often arrives sideways rather than as a peak experience. That’s not a flaw in the medicine. It’s the medicine doing its work. The case the Hopkins researchers have been making is essentially modest. They’re not promising salvation. They’re saying the evidence supports treating psilocybin as a useful clinical tool with a manageable risk profile, and that policy should reflect that. For readers who arrived here trying to figure out whether plant medicine has any real legitimacy, that’s probably the most grounded answer available right now. The scientists who’ve looked at it most carefully think it works, think it’s reasonably safe under the right conditions, and think the law is overdue for an update. What you do with that information is, as it always was, your own call.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
